TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...

Myriad Genetics (MYGN) announced that the United States Patent and Trademark Office has issued two new patents that further advance Myriad’s ability to bring its tumor-informed, high-definition, ...

How do bacteria - harmless ones living in our bodies, or those that cause disease - organize their activities? A new study, combining powerful genomic-scale microscopy with a technical innovation, ...